EXACT Sciences Co. (NASDAQ:EXAS) has received a consensus rating of “Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $109.40.
A number of equities research analysts have recently issued reports on EXAS shares. Craig Hallum restated a “buy” rating and set a $115.00 price objective (up previously from $95.00) on shares of EXACT Sciences in a report on Wednesday, May 1st. BidaskClub upgraded EXACT Sciences from a “hold” rating to a “buy” rating in a report on Friday, March 15th. Goldman Sachs Group upgraded EXACT Sciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $85.00 to $120.00 in a report on Tuesday, February 26th. BTIG Research boosted their price objective on EXACT Sciences to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Finally, Zacks Investment Research cut EXACT Sciences from a “hold” rating to a “sell” rating in a report on Thursday, March 21st.
EXACT Sciences stock traded down $2.26 during midday trading on Tuesday, reaching $111.51. 45,589 shares of the company’s stock were exchanged, compared to its average volume of 1,667,387. EXACT Sciences has a 52 week low of $47.78 and a 52 week high of $117.98. The company has a current ratio of 8.39, a quick ratio of 8.13 and a debt-to-equity ratio of 1.02. The company has a market cap of $14.61 billion, a price-to-earnings ratio of -81.79 and a beta of 1.68. The firm has a 50-day moving average price of $103.24.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, April 30th. The medical research company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. The business had revenue of $162.00 million for the quarter, compared to the consensus estimate of $153.07 million. During the same quarter in the previous year, the business posted ($0.33) EPS. The company’s revenue for the quarter was up 79.4% on a year-over-year basis. On average, sell-side analysts expect that EXACT Sciences will post -2.21 earnings per share for the current year.
In other EXACT Sciences news, insider Mark Stenhouse sold 11,192 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $92.54, for a total transaction of $1,035,707.68. Following the sale, the insider now owns 25,500 shares of the company’s stock, valued at $2,359,770. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.20% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. First Hawaiian Bank boosted its position in EXACT Sciences by 160.0% during the first quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 200 shares during the last quarter. Buffington Mohr McNeal bought a new stake in EXACT Sciences during the first quarter valued at $30,000. Mosaic Family Wealth LLC bought a new stake in EXACT Sciences during the first quarter valued at $37,000. Karp Capital Management Corp bought a new stake in EXACT Sciences during the fourth quarter valued at $38,000. Finally, Shine Investment Advisory Services Inc. boosted its position in EXACT Sciences by 130.2% during the first quarter. Shine Investment Advisory Services Inc. now owns 442 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 250 shares during the last quarter. 86.27% of the stock is currently owned by institutional investors and hedge funds.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
See Also: Call Option Volume
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.